



## Prior Authorization Approval Criteria

### Zofran (ondansetron)

**Generic name:** ondansetron

**Brand name:** Zofran

**Medication class:** 5HT3 antiemetic

**FDA approved uses:** Prevention of nausea and vomiting associated with emetogenic cancer chemotherapy; prevention of nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen; postoperative nausea and vomiting; prophylaxis.

**Other uses:** Hyperemesis gravidarum

**Usual dose:** *Prevention of nausea and vomiting associated with chemotherapy or radiation therapy:* 8 mg every 8 hours for 1-2 doses beginning 30 minutes prior to chemotherapy or 1-2 hours prior to radiation therapy followed by 8 mg every 12-24 hours for 1-2 days after chemotherapy or radiation therapy.  
*Postoperative nausea and vomiting:* 8-16 mg 1 hour prior to surgery  
*Hyperemesis gravidarum:* Determined by prescriber.

**Duration of therapy:** *Prevention of nausea and vomiting associated with chemotherapy or radiation therapy:* 3 days total.  
*Postoperative nausea and vomiting:* 1 day  
*Hyperemesis gravidarum:* Up to the duration of pregnancy.

**Criteria for use:** *(bullet points below are all inclusive unless otherwise noted)*

- Nausea and vomiting due to chemotherapeutic agents.
  - Allowed for up to 3 times a day for 3 days post chemotherapy.
  - Acute use only, not for chronic use for non-chemotherapy emesis
- OR**
- Use in pregnant woman who have failed conventional antiemetic therapy (ie. promethazine, prochlorperazine) and are at risk of dehydration and require IV fluids.
- OR**
- Treatment of post-operative nausea and vomiting
- OR**
- Prevention of nausea and vomiting associated with radiotherapy

P&T Approval: \_\_\_\_\_ Date: \_\_\_\_\_  
Adopted: 11/19/04